Sunday, June 09, 2019 9:53:15 PM
https://www.rns-pdf.londonstockexchange.com/rns/8119H_1-2018-11-19.pdf
and then docket#58884, the judge's response and order to the matter in the US Bk Court. BTW, the judge ruled against the issuance of substitute preferred shares by LBHI. The funds LBHI was holding as to the ECAPs have been transferred to the UK liquidator. All this is noted in the docs above. Obviously RSM Advisory was representing ECAP holders in Europe, and yes they DID have grounds to stop LBHI efforts to issue substitute preferred shares. Again, read the document link above from RSM Advisory as a joint liquidator. This is not my opinion. Read the docs!
The ECAPs are very different from the CTs. The ECAPs have both the UK unit, LBH, and LBHI guarantees. The CTs only have the LBHI guarantee. Much is made of this "global guarantee". Yes, there is a guarantee, but it is a guarantee subject the ranking as well with the CTs being subordinated debt, and junior to senior debt.
Stoxjock, You think you are on to something here. I will ask you. Why doesn't the market agree with you. If there was any chance at all to a recovery investors would be will to pay much more than 10 cents a share just to have a "option" of a possible payout?
There is no thievery. Shareholders here simply do not understand the process and don't fully understand what they own and its limitations.
Answer one question for me. Do you know why LBHI wanted to issue substitute preferred shares? If so, let's hear it. Your answer will be very telling if you really know what is going on with the ECAPs.
I am not the enemy of you CT holders. You all's insufficient knowledge of the process is. The CTs have no pathway of seeing a recovery. They are worth zero in the end. Wu's motion will go nowhere.
Joe Stocks
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM